Free Trial

C4X Discovery (C4XD) Competitors

GBX 12
+2.58 (+27.32%)
(As of 04/25/2024)

C4XD vs. OBD, HEMO, AREC, OBI, ONC, OPTI, SBTX, TRX, SAR, and NSCI

Should you be buying C4X Discovery stock or one of its competitors? The main competitors of C4X Discovery include Oxford BioDynamics (OBD), Hemogenyx Pharmaceuticals (HEMO), Arecor Therapeutics (AREC), Ondine Biomedical (OBI), Oncimmune (ONC), OptiBiotix Health (OPTI), SkinBioTherapeutics (SBTX), Tissue Regenix Group (TRX), Sareum (SAR), and NetScientific (NSCI). These companies are all part of the "biotechnology" industry.

C4X Discovery vs.

C4X Discovery (LON:C4XD) and Oxford BioDynamics (LON:OBD) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, media sentiment, risk, community ranking, profitability, institutional ownership, analyst recommendations, earnings and valuation.

In the previous week, Oxford BioDynamics had 2 more articles in the media than C4X Discovery. MarketBeat recorded 3 mentions for Oxford BioDynamics and 1 mentions for C4X Discovery. C4X Discovery's average media sentiment score of 0.67 beat Oxford BioDynamics' score of 0.13 indicating that C4X Discovery is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
C4X Discovery
0 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Oxford BioDynamics
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

C4X Discovery has a net margin of 42.81% compared to Oxford BioDynamics' net margin of 0.00%. C4X Discovery's return on equity of 55.38% beat Oxford BioDynamics' return on equity.

Company Net Margins Return on Equity Return on Assets
C4X Discovery42.81% 55.38% 28.04%
Oxford BioDynamics N/A -250.52%-46.27%

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
C4X Discovery
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00
Oxford BioDynamics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
N/A

52.1% of C4X Discovery shares are held by institutional investors. Comparatively, 36.5% of Oxford BioDynamics shares are held by institutional investors. 27.1% of C4X Discovery shares are held by company insiders. Comparatively, 15.5% of Oxford BioDynamics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

C4X Discovery has a beta of 0.23, indicating that its stock price is 77% less volatile than the S&P 500. Comparatively, Oxford BioDynamics has a beta of 0.46, indicating that its stock price is 54% less volatile than the S&P 500.

C4X Discovery has higher revenue and earnings than Oxford BioDynamics. Oxford BioDynamics is trading at a lower price-to-earnings ratio than C4X Discovery, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
C4X Discovery£24.68M1.23£10.57M£0.04300.00
Oxford BioDynamics£176K135.29-£10.83M-£0.07-109.07

Oxford BioDynamics received 16 more outperform votes than C4X Discovery when rated by MarketBeat users. However, 77.88% of users gave C4X Discovery an outperform vote while only 61.54% of users gave Oxford BioDynamics an outperform vote.

CompanyUnderperformOutperform
C4X DiscoveryOutperform Votes
88
77.88%
Underperform Votes
25
22.12%
Oxford BioDynamicsOutperform Votes
104
61.54%
Underperform Votes
65
38.46%

Summary

C4X Discovery beats Oxford BioDynamics on 12 of the 16 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding C4XD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

C4XD vs. The Competition

MetricC4X DiscoveryBiotechnology IndustryMedical SectorLON Exchange
Market Cap£30.27M£189.88M£5.05B£1.43B
Dividend YieldN/A3.42%44.98%11.83%
P/E Ratio300.00244.01116.091,701.59
Price / Sales1.2316,125.782,419.13297,515.10
Price / Cash4.0011.2532.6632.84
Price / Book1.206.215.032.72
Net Income£10.57M-£18.18M£103.33M£165.28M
7 Day PerformanceN/A0.25%1.03%3.93%
1 Month Performance45.90%5.16%5.74%5.69%
1 Year Performance-27.60%5.89%7.32%11.42%

C4X Discovery Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
OBD
Oxford BioDynamics
0 of 5 stars
GBX 7.90
+0.1%
N/A-53.9%£24.64M£176,000.00-112.8645Gap Down
HEMO
Hemogenyx Pharmaceuticals
0 of 5 stars
GBX 1.56
-2.2%
N/A-31.3%£20.90MN/A-156.0014News Coverage
Gap Down
AREC
Arecor Therapeutics
0 of 5 stars
GBX 136.50
flat
N/A-42.5%£41.81M£3.38M-440.3251News Coverage
OBI
Ondine Biomedical
0 of 5 stars
GBX 6.60
flat
N/A-59.1%£18.30M£856,000.00-110.00N/A
ONC
Oncimmune
0 of 5 stars
GBX 24.30
-2.0%
N/A-29.5%£18.02M£1.15M-303.7552Gap Down
OPTI
OptiBiotix Health
0 of 5 stars
GBX 18
flat
N/A+83.2%£17.63M£1.26M-120.009
SBTX
SkinBioTherapeutics
0 of 5 stars
GBX 8.60
flat
N/A-42.0%£17.23M£21,949.00-430.0011Gap Up
TRX
Tissue Regenix Group
0 of 5 stars
GBX 62
+0.8%
N/A+12.4%£43.75M£29.49M-3,100.0082
SAR
Sareum
0.828 of 5 stars
GBX 41.75
+14.4%
GBX 304
+628.1%
-75.4%£44.61M£47,204.00-695.835Gap Up
High Trading Volume
NSCI
NetScientific
0 of 5 stars
GBX 64
-0.8%
N/A-0.5%£15.33M£1.38M-492.3126

Related Companies and Tools

This page (LON:C4XD) was last updated on 5/21/2024 by MarketBeat.com Staff

From Our Partners